Gyorgy Baffy, M.D., Ph.D.
Associate Professor of Medicine
Veterans Affairs Boston Healthcare System
V.A. Veterans Admin Med Ctr
150 S Huntington Ave
Jamaica Plain MA 02130
|University of Debrecen, Debrecen, Hungary||MD||1980||Medicine|
|University of Debrecen, Debrecen, Hungary||1987||Gastroenterology|
|University of Pennsylvania, Philadelphia, PA||1993||Biochemistry|
|National Academy of Sciences, Budapest, Hungary||PhD||1994||Medicine|
|University of Michigan, Ann Arbor, MI||1996||Gastroenterology|
|Brigham and Women's Hospital, Boston, MA||2001||Gastroenterology|
OMGE Young Investigator Scholarship
1991 - 1993
NIH Fogarty Fellow
2014 - 2015
US Fulbright Scholar Award
Pro Optimo Merito in Gastroenterologia
Dr. Gyorgy Baffy is an Associate Professor of Medicine at Harvard Medical School and Chief of Gastroenterology at the VA Boston Healthcare System. He is a graduate of the University Medical School of Debrecen in Hungary. He received his PhD from his studies conducted on growth factor-mediated calcium signaling in hepatocytes as an NIH Fogarty Fellow in the Department of Biochemistry and Biophysics at the University of Pennsylvania. He trained in gastroenterology at the University of Michigan and the Brigham and Women’s Hospital. His research interests focus on various aspects of NAFLD such as risk stratification, biomarkers, metabolic reprogramming, cancer bioenergetics, pathophysiology of portal hypertension, and development of hepatocellular carcinoma. He has been involved in several clinical trials related to cirrhosis management and colorectal cancer screening. He developed and organized multiple regional, national, and international workshops and symposia. He published over 100 peer-reviewed papers and book chapters. He has been a member of various scientific review panels and provides editorial work for major journals in gastroenterology and hepatology. In 2014, he received a Fulbright US Scholar award to teach for a semester about obesity and related disorders at the University of Debrecen. He is a Fellow of the American College of Physicians, American College of Gastroenterology, American Gastroenterological Association, and the American Association for the Study of Liver Diseases. He is the recipient of the Madaus Prize from the Madaus Liver Foundation and the Hetényi Medal and Pro Optimo Merito in Gastroenterologia Award from the Hungarian Gastroenterological Association.
The research activities and funding listed below are automatically derived from
NIH ExPORTER and other sources, which might result in incorrect or missing items.
to make corrections and additions.
(IOANNOU, GEORGE / TADDEI, TAMAR)
May 1, 2023 - Apr 30, 2032
VA Office of Research & Development Cooperative Studies Program
PREventing Liver Cancer Mortality through Imaging with Ultrasound vs. MRI (PREMIUM)
Role Description: The main objective of this multicenter randomized controlled trial is to compare the efficacy of biannual ultrasound plus alpha-fetoprotein (AFP) vs. biannual abbreviated magnetic resonance imaging (MRI) plus AFP as cancer screening modalities for patients with cirrhosis with a primary outcome of HCC-related mortality.
(KAPLAN, DAVID / TADDEI, TAMAR)
Oct 1, 2020 - Sep 30, 2025
VA ORD Clinical Science Research & Development
Effect of simvastatin on hepatic decompensation and death in subjects with high- risk compensated cirrhosis (SACRED: Statins and Cirrhosis: Reducing Events of Decompensation
Role Description: The primary objective of this phase III, randomized, double-blind, placebo-controlled, multicenter trial is to demonstrate that statin therapy can reduce the rate of hepatic decompensation, hepatocellular carcinoma, all-cause mortality, and the need for liver transplantation
(NAVARRO, VICTOR / VERMA, MANISHA)
Oct 1, 2017 - Sep 30, 2024
Patient-Centered Outcomes Research Institute (PCORI)
Introducing palliative care with the treatment of end stage liver disease: A randomized controlled trial
Role Description: The main goal of this multicenter cluster randomized clinical project is to determine the benefits of hepatologist-led palliative care compared to the conventional approach of requesting palliative care consultations in the management of patients with end-stage liver disease
(DOMINITZ, JASON / ROBERTSON, DOUGLAS)
May 1, 2012 - Sep 30, 2027
Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM)
Role Description: The main goal of this study is to perform a large, simple, multicenter, randomized, parallel group trial directly comparing screening colonoscopy with annual fecal immunochemistry test (FIT) screening in 50,000 average risk individuals and determine whether colonoscopy is superior to FIT in the prevention of colorectal cancer mortality measured over 10 years.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.